PBLA - Panbela Publishes Preclinical and Clinical Data

2023-11-02 08:56:59 ET

DENVER, Colo., Nov 2, 2023 ( www.247marketnews.com )- Panbela Therapeutics Inc (NASDAQ: PBLA) stated, this morning, that it published preclinical and clinical data from studies of CPP-1X (also known as ?-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes (T1D), showing that DFMO treatment may provide metabolic benefits to preserve ? cell function and health in T1D.

Panbela Therapeutics is trading at $1.12, up $0.323  (+40.62%), on 3.18M premarket shares traded.

Its 52-week range is $0.70 to $295.20. It hit a new 52-week low last week and this looks like it may be a potential trend reversal.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our …

The post Panbela Publishes Preclinical and Clinical Data appeared first on 24/7 Market News .

For further details see: